research use only

LY-3381916 IDO/TDO inhibitor

Cat.No.S8919

LY-3381916 (IDO1-IN-5) is a brain penetrated, potent and selective Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor. This compound exhibits anti-tumor activity.
LY-3381916 IDO/TDO inhibitor Chemical Structure

Chemical Structure

Molecular Weight: 396.45

Quality Control

Batch: S891901 DMSO]79 mg/mL]false]Ethanol]20 mg/mL]false]Water]Insoluble]false Purity: 99.82%
99.82

Chemical Information, Storage & Stability

Molecular Weight 396.45 Formula
C23H25FN2O3
Storage (From the date of receipt) 3 years -20°C powder
CAS No. 2166616-75-5 -- Storage of Stock Solutions

Synonyms IDO1-IN-5 Smiles CC(C1=CC2=C(C=C1)N(CC2)C(=O)C3CCOCC3)NC(=O)C4=CC=C(C=C4)F

Solubility

In vitro
Batch:

DMSO : 79 mg/mL ( (199.26 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Ethanol : 20 mg/mL

Water : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC50/Ki
IDO1 [1]
In vitro

LY3381916 binds to newly synthesized apo-IDO1 lacking heme, but does not inhibit mature heme-bound IDO1. Protein x-ray crystallography confirms that this compound binds to apo-IDO1 where it occupies the heme-binding pocket of IDO1. Modeling of the pre-clinical PK/PD relationship suggests QD dosing of this chemical will maintain greater than 90% inhibition over 24 hours. In addition, due to the favorable properties of the drug, significant central nervous system (CNS) penetration has been measured for this compound.[1]

References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03343613 Terminated
Solid Tumor|Non Small Cell Lung Cancer|Renal Cell Carcinoma|Triple Negative Breast Cancer
Eli Lilly and Company
November 17 2017 Phase 1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.